Hydroxychloroquine Clinical Trial
Verified date | February 2018 |
Source | Peking University First Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 200-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 8, 2018 |
Est. primary completion date | January 8, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - primary IgA nephropathy - age 18-75 years - proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB - eGFR>30ml/min/1.73m2 Exclusion Criteria: - immune suppressive agent in recent one years - crescent glomerulonephritis, might use immune suppressive agent - chronic hepatic disease - myocardial infarction - malignant hypertension - stroke - malignant tumor - retinopathy - other contraindication of Hydroxychloroquine - pregnancy and breastfeeding women - life expectancy for less than 6 months - in other clinical trials - not suitable for the study judged by investigator |
Country | Name | City | State |
---|---|---|---|
China | Peking University First Hospital | BeiJing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University First Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proteinuria (g/d) | every two months(total six months) | ||
Secondary | Albuminuria and creatinine ratio(mg/g) | every two months(total six months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Completed |
NCT04347798 -
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
|
||
Completed |
NCT04652648 -
Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts
|
Phase 4 | |
Withdrawn |
NCT04354441 -
Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women
|
Phase 2 | |
Completed |
NCT04434144 -
A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
|
||
Active, not recruiting |
NCT04363827 -
Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)
|
Phase 2 | |
Completed |
NCT04376814 -
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
|
N/A | |
Enrolling by invitation |
NCT04340349 -
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals
|
Early Phase 1 | |
Completed |
NCT02648464 -
Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial
|
Phase 4 | |
Not yet recruiting |
NCT05647330 -
Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT04349228 -
Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals
|
Phase 3 | |
Recruiting |
NCT04363450 -
Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)
|
Phase 3 | |
Not yet recruiting |
NCT04352946 -
HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial
|
Phase 3 | |
Recruiting |
NCT05451277 -
At the Heart of the Matter - Speckle Tracking Echocardiography in Lupus Mothers and Their Offspring
|